Nowadays, many people are aware of self-care, and one of the most popular ones in the past few years is to take small doses of aspirin orally every day, which can prevent the risk of cardiovascular and cerebrovascular accidents, as well as the occurrence of various tumors, such as intestinal cancer, lung cancer, etc. It can be considered a miracle drug. Recently, there was a report that did a study on the relationship between lung cancer and aspirin. This study included 14,735 patients diagnosed with lung cancer between 1998 and 2009, and collected information and lung cancer-related deaths. A Cox risk proportional model was used to calculate the association between low-dose aspirin use and lung cancer-specific mortality before and after lung cancer diagnosis. Analysis of data from 3,635 lung cancer patients showed that low-dose aspirin use after lung cancer diagnosis did not reduce lung cancer-related mortality, and similarly low-dose aspirin use before lung cancer diagnosis did not reduce the risk of lung cancer-related mortality. The findings suggest that the data from this large population-based lung cancer cohort study do not support a lower risk of lung cancer-related death with low-dose aspirin. In this study, I would like to say that there is a lack of a large-scale clinical study on whether aspirin reduces the risk of lung cancer development or death after lung cancer diagnosis in our Chinese population, and it is unknown whether it has a significant effect in Europe and the United States, or in our Asian population.